MARKET

TRVN

TRVN

Trevena Inc
NASDAQ
0.4586
+0.0153
+3.45%
Closed 16:00 03/27 EDT
OPEN
0.4560
PREV CLOSE
0.4433
HIGH
0.4625
LOW
0.4400
VOLUME
68.13K
TURNOVER
0
52 WEEK HIGH
3.280
52 WEEK LOW
0.4068
MARKET CAP
8.40M
P/E (TTM)
-0.1567
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TRVN last week (0318-0322)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The company's market cap stands at $8.0 billion. Masimo shares rose 12.48% and NextCure shares declined by 9.5% during the same session.
Benzinga · 5d ago
Trevena Inc: Current report
Press release · 6d ago
Weekly Report: what happened at TRVN last week (0311-0315)?
Weekly Report · 03/18 10:18
HC Wainwright & Co. Reiterates Buy on Trevena, Maintains $9 Price Target
Benzinga · 03/11 10:50
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN), MoonLake Immunotherapeutics (MLTX) and Senseonics Holdings (SENS)
TipRanks · 03/11 10:40
Weekly Report: what happened at TRVN last week (0304-0308)?
Weekly Report · 03/11 10:16
Weekly Report: what happened at TRVN last week (0226-0301)?
Weekly Report · 03/04 10:18
More
About TRVN
Trevena, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company's product, OLINVYK (oliceridine) injection, is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. It is also engaged in three differentiated investigational drug candidates: TRV045, TRV250, and TRV734. TRV045 is a novel sphingosine-1-phosphate (S1P), receptor modulator that may offer a new, non-opioid approach to managing chronic pain, as well as treating epilepsy and seizure disorders. TRV250 is a G-protein biased delta-opioid receptor (DOR), agonist as a compound with a mechanism for the treatment of acute migraine. TRV734 is a new chemical entity (NCE) targeting the same mechanism of action at the mu-opioid receptor (MOR). TRV734 is used for the treatment of opioid use disorder.

Webull offers Trevena Inc stock information, including NASDAQ: TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.